• Aktuelle Seite:  
  • Home
  • Substitution und Schwangerschaft
A- A A+

Maternal Buprenorphine Split Dosing

Authors: Flores C., Riaz U., Tenore P., and Muhammad N.

Heroin Addiction and Related Clinical Problems, Published Ahead of Print, August 9, 2023

https://www.heroinaddictionrelatedclinicalproblems.org/harcp-archives-doi-articles.php

Pregnancy related hormones increase CYP3A mediated buprenorphine metabolism in human hepatocytes: a comparison to CYP3A substrates nifedipine and midazolam. 

Fashe MM, Miner TA, Fallon JK, Schauer AP, Sykes C, Smith PC, Lee CR. 

Front Pharmacol. 2023 Jul 5;14:1218703. doi: 10.3389/fphar.2023.1218703. PMID: 37475714; PMCID: PMC10354249.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10354249/

IRIS. Du bist schwanger oder willst es werden? Dann fang jetzt an mit dem Aufhören.

Jede Schwangerschaft ist wie ein Wunder. Damit es deinem Kind von Anfang an gut geht, hilft IRIS dir dabei, mit dem Rauchen aufzuhören und auf Alkohol zu verzichten. (aufgerufen am 13.09.2023)

IRIS macht dich frei. Für dein neues Leben.

https://www.iris-plattform.de/

Principles of care for pregnant and parenting people with substance use disorder: the obstetrician gynecologist perspective. 

Barber CM, Terplan M. 

Front Pediatr. 2023 May 24;11:1045745. doi: 10.3389/fped.2023.1045745. PMID: 37292372; PMCID: PMC10246753.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10246753/

Opioid Use Disorder During Breastfeeding. 

Anderson PO. 

Breastfeed Med. 2023 Jun;18(6):410-412. doi: 10.1089/bfm.2023.0088. Epub 2023 Apr 26. PMID: 37102692.

https://www.liebertpub.com/doi/10.1089/bfm.2023.0088

A systematic review of in utero cannabis exposure and risk for structural birth defects. 

Sujan AC, Pal A, Avalos LA, Young-Wolff KC. 

Front Pediatr. 2023 May 25;11:1149401. doi: 10.3389/fped.2023.1149401. PMID: 37303758; PMCID: PMC10248236.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10248236/

Association between maternal benzodiazepine or Z-hypnotic use in early pregnancy and the risk of stillbirth, preterm birth, and small for gestational age: a nationwide, population-based cohort study in Taiwan

Meng, Lin-Chieh et al.

The Lancet Psychiatry, Volume 10, Issue 7, 499 - 508 

Abstract

https://www.thelancet.com/journals/lanpsy/article/PIIS2215-0366(23)00148-7/fulltext

Advisory: Evidence-Based, Whole Person Care of Pregnant People Who Have Opioid Use Disorder

This Advisory outlines how healthcare providers (i.e., obstetrician-gynecologists [OB-GYNs], primary care physicians, and other professionals who treat pregnant people) can take an active role in supporting the health of pregnant individuals who have OUD and their babies. (SAMHSA - Substance Abuse and Mental Health Services Administration, USA, Mai 2023)

https://store.samhsa.gov/product/advisory-evidence-based-whole-person-care-pregnant-people-opioid-use-disorder/pep23-02-01-002

Prescribed and Penalized: The Detrimental Impact of Mandated Reporting for Prenatal Utilization of Medication for Opioid Use Disorder. 

Work, E.C., Muftu, S., MacMillan, K.D.L. et al.

Matern Child Health J (2023). doi.org/10.1007/s10995-023-03672-x

https://link.springer.com/article/10.1007/s10995-023-03672-x

Harmful effects of opioid use in pregnancy: A scientific review commissioned by the European Board and College of obstetrics and gynaecology (EBCOG). 

Vella A, Savona-Ventura C, Mahmood T. 

Eur J Obstet Gynecol Reprod Biol. 2023 May 18;286:70-75. doi: 10.1016/j.ejogrb.2023.05.019. Epub ahead of print. PMID: 37216740.

https://ebcog.eu/wp-content/uploads/2023/06/Harmful-effects-of-opioids-during-pregnancy.pdf

The impact of timing of in utero marijuana exposure on fetal growth. 

Dodge P, Nadolski K, Kopkau H, Zablocki V, Forrestal K, Bailey BA. 

Front Pediatr. 2023 May 16;11:1103749. doi: 10.3389/fped.2023.1103749. PMID: 37260795; PMCID: PMC10228645.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10228645/

Opioid Agonist Therapies and Pregnancy Outcomes for Pregnant People With Opioid Use Disorder: Protocol for a Systematic Review. 

Wilson LA, Gandhi P. 

JMIR Res Protoc. 2023 May 10;12:e42417. doi: 10.2196/42417. PMID: 37163329; PMCID: PMC10209784.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10209784/

P-glycoprotein efflux transporter: a key to pharmacokinetic modeling for methadone clearance in fetuses. 

Ho H, Zhang E. 

Front Pharmacol. 2023 May 4;14:1182571. doi: 10.3389/fphar.2023.1182571. PMID: 37214474; PMCID: PMC10192552.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10192552/

Methadone alters transcriptional programs associated with synapse formation in human cortical organoids. 

Dwivedi I, Caldwell AB, Zhou D, Wu W, Subramaniam S, Haddad GG. 

Transl Psychiatry. 2023 May 6;13(1):151. doi: 10.1038/s41398-023-02397-3. PMID: 37147277; PMCID: PMC10163238.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10163238/

USA. Advisory: Evidence-Based, Whole Person Care of Pregnant People Who Have Opioid Use Disorder

This Advisory outlines how healthcare providers (i.e., obstetrician-gynecologists [OB-GYNs], primary care physicians, and other professionals who treat pregnant people) can take an active role in supporting the health of pregnant individuals who have OUD and their babies. (Substance Abuse and Mental Health Services Administration (SAMHSA), USA, aufgerufen am 24.05.2023)

https://www.samhsa.gov/resource/ebp/advisory-whole-person-care-pregnant-people-opioid-use-disorder

Pain Management After Cesarean Delivery Among Women with Opioid Use Disorder: Results from a Retrospective Pregnancy Cohort in a Rural Region of the Midwest.

Riddle J, Botsford JA, Dean S, Coffman C, Robinson CA, Kerver JM. 

Womens Health Rep (New Rochelle). 2023 Apr 13;4(1):154-161. doi: 10.1089/whr.2022.0108. PMID: 37096126; PMCID: PMC10122217.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10122217/

Inpatient Buprenorphine Induction for Opioid Use Disorder in Pregnancy. 

Tavakoli A, Donovan K, Sweeney H, Uquillas K, Gordon B. 

Cureus. 2023 Mar 19;15(3):e36376. doi: 10.7759/cureus.36376. PMID: 37090287; PMCID: PMC10113565.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10113565/

Biopsychosocial contexts of timely and adequate prenatal care utilization among women with criminal legal involvement and opioid use disorder. 

Satcher MF, Bruce ML, Goodman DJ, Lord SE. 

BMC Public Health. 2023 Apr 21;23(1):729. doi: 10.1186/s12889-023-15627-6. PMID: 37085842; PMCID: PMC10119004.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10119004/

Medication for Opioid Use Disorder During Pregnancy - Maternal and Infant Network to Understand Outcomes Associated with Use of Medication for Opioid Use Disorder During Pregnancy (MAT-LINK), 2014-2021. 

Miele K, Kim SY, Jones R, Rembert JH, Wachman EM, Shrestha H, Henninger ML, Kimes TM, Schneider PD, Sivaloganathan V, Sward KA, Deshmukh VG, Sanjuan PM, Maxwell JR, Seligman NS, Caveglia S, Louis JM, Wright T, Bennett CC, Green C, George N, Gosdin L, Tran EL, Meaney-Delman D, Gilboa SM. 

MMWR Surveill Summ. 2023 May 5;72(3):1-14. doi: 10.15585/mmwr.ss7203a1. PMID: 37130060; PMCID: PMC10154076.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10154076/

Collaborative care programs for pregnant and postpartum individuals with opioid use disorder: Organizational characteristics of sites participating in the NIDA CTN0080 MOMs study. 

Kropp FB, Smid MC, Lofwall MR, Wachman EM, Martin PR, Murphy SM, Wilder CM, Winhusen TJ. 

J Subst Use Addict Treat. 2023 Apr 4;149:209030. doi: 10.1016/j.josat.2023.209030. Epub ahead of print. PMID: 37023858.

https://www.sciencedirect.com/science/article/pii/S2949875923000802

Postpartum Opioid-Related Mortality in Patients With Public Insurance. 

Suarez, Elizabeth A. PhD, MPH; Huybrechts, Krista F. MS, PhD; Straub, Loreen MD, MS; Hernández-Díaz, Sonia MD, DrPH; Creanga, Andreea A. MD, PhD; Connery, Hilary S. MD, PhD; Gray, Kathryn J. MD, PhD; Vine, Seanna M. MPH; Jones, Hendrée E. PhD; Bateman, Brian T. MD, MS. 

Obstetrics & Gynecology ():10.1097/AOG.0000000000005115, March 9, 2023. | DOI: 10.1097/AOG.0000000000005115

https://journals.lww.com/greenjournal/Fulltext/9900/Postpartum_Opioid_Related_Mortality_in_Patients.710.aspx

In utero methadone exposure permanently alters anatomical and functional connectivity: A preclinical evaluation. 

Chin EM, Kitase Y, Madurai NK, Robinson S, Jantzie LL. 

Front Pediatr. 2023 Feb 23;11:1139378. doi: 10.3389/fped.2023.1139378. PMID: 36911026; PMCID: PMC9995894.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9995894/

Successful Buprenorphine/Naloxone Low-dose Induction in Pregnancy: A Case Report. 

Coish R, Hardial J. 

J Addict Med. 2023 Jan-Feb 01;17(1):114-116. doi: 10.1097/ADM.0000000000001042. Epub 2022 Aug 2. PMID: 35916416; PMCID: PMC9897269.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9897269/

Safety and Efficacy of Buprenorphine-Naloxone in Pregnancy: A Systematic Review of the Literature. 

Ordean A, Tubman-Broeren M. 

Pathophysiology. 2023 Feb 11;30(1):27-36. doi: 10.3390/pathophysiology30010004. PMID: 36810423; PMCID: PMC9944489.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9944489/

Cluster analysis to identify patient profiles and substance use patterns among pregnant persons with opioid use disorder. 

Charron E, Yu Z, Lundahl B, Silipigni J, Okifuji A, Gordon AJ, Baylis JD, White A, Carlston K, Abdullah W, Haaland B, Krans EE, Smid MC, Cochran G. 

Addict Behav Rep. 2023 Feb 15;17:100484. doi: 10.1016/j.abrep.2023.100484. PMID: 36844693; PMCID: PMC9950438.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9950438/

Obstetric pain management for pregnant women with opioid use disorder: A qualitative and quantitative comparison of patient and provider perspectives (QUEST study). 

Nowakowski, E, Dayananda, S, Morgan, M, Jarvis, O, Altamirano, V, LaSorda, KR, et al. Addiction. 2023. doi.org/10.1111/add.16134

https://onlinelibrary.wiley.com/doi/full/10.1111/add.16134

Psychiatric comorbidities and their treatment predict buprenorphine continuation among postpartum people with opioid use disorder. 

Shadowen H, Violante S, Gataric A, Goulding AN, Martin CE. 

Drug Alcohol Depend Rep. 2022 Dec;5:100121. doi: 10.1016/j.dadr.2022.100121. Epub 2022 Nov 19. PMID: 36644222; PMCID: PMC9835555.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9835555/

How does a clinician approach the pharmacological management of opioid use disorders in pregnant women and pregnant people? 

Jones HE. 

Expert Opin Pharmacother. 2023 Jan 12:1-5. doi: 10.1080/14656566.2023.2165909. Epub ahead of print. PMID: 36628440.

https://www.tandfonline.com/doi/full/10.1080/14656566.2023.2165909

Harm Reduction Approach to Increasing Self-reported Safe Medication Storage Among Pregnant and Parenting People Receiving Opioid Use Disorder Treatment. 

Grist E, Thakkar B, Dacha P, Lutins E, Maxwell M, Martin CE. 

J Addict Med. 2022 Oct 27. doi: 10.1097/ADM.0000000000001087. Epub ahead of print. PMID: 36730907.

Abstract

https://pubmed.ncbi.nlm.nih.gov/36730907/

Heavy prenatal alcohol exposure and overall morbidities: a Danish nationwide cohort study from 1996 to 2018

Broccia, Marcella et al.

The Lancet Public Health, Volume 8, Issue 1, e36 - e46 

https://www.thelancet.com/journals/lanpub/article/PIIS2468-2667(22)00289-4/fulltext

  1. Heavy prenatal alcohol exposure and obstetric and birth outcomes: a Danish nationwide cohort study from 1996 to 2018
  2. Buprenorphine-naloxone, buprenorphine, and methadone throughout pregnancy in maternal opioid use disorder. 
  3. USA. Overdose Deaths up 81% in Pregnant, Postpartum
  4. Association of Prenatal Exposure to Benzodiazepines With Development of Autism Spectrum and Attention-Deficit/Hyperactivity Disorders. 
  5. Maternal methadone split dosing in pregnancy